secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001831283-23-000034
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio reports FY2022 net loss of $110.3M; cash $302.4M with runway through end of 2024
--------------------------------------------------------------------------------

- Net loss $18.3M in Q4 2022 ($21.2M in Q4 2021); FY2022 loss $110.3M vs $196.3M in 2021.
- Cash, cash equivalents and marketable securities $302.4M at Dec 31, 2022, down $100.8M from 2021.
- Phase 3 EXPLORER-CN trial of mavacamten completed patient visits; topline data expected mid-2023.
- Entered commercial agreement with Pfizer for sisunatovir; received $20M upfront, eligible for up to $135M milestones.
- Phase 3 LIBRA trial of TP-03 for Demodex blepharitis ongoing; data expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000034/0001831283-23-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000034/lian-20230327.htm
  HTML page:      https://secwatch.observer/filing/0001831283-23-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer